SCHEMBL21296892

SCHEMBL21296892

O=C(O)c1nn[nH]c1Oc1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
CA12 O43570 1/20 0.43
MIF P14174 1/20 0.42
MEN1 O00255 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTPN7 P35236 1/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
EGLN1 Q9GZT9 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
SIRT3 Q9NTG7 1/20 0.41
ENPP3 O14638 1/20 0.40
ALPL P05186 1/20 0.40
ENPP1 P22413 1/20 0.40
XIAP P98170 1/20 0.40
FLT3 P36888 1/20 0.40
HAO1 Q9UJM8 3/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799273 1.00 KMT2A (0.43) KMT2ACA12MIFMEN1L3MBTL1
SCHEMBL21296909 0.89 CA12 (0.48) KMT2ACA12MIFMEN1EGLN1
SCHEMBL29799213 0.89 CA12 (0.48) KMT2ACA12MIFMEN1EGLN1
SCHEMBL21296868 0.87 CA12 (0.46) CA12MIFSIRT2ALPLHAO1
SCHEMBL29799100 0.87 CA12 (0.46) CA12MIFSIRT2ALPLHAO1
SCHEMBL21296882 0.85 HAO1 (0.44) KMT2AMAPTHAO1
SCHEMBL21296854 0.82 HAO1 (0.44) HAO1
SCHEMBL29799085 0.82 HAO1 (0.44) HAO1FABP7FABP3MRGPRX4
SCHEMBL21296859 0.82 HAO1 (0.44) HAO1FABP7FABP3MRGPRX4
SCHEMBL21296846 0.80 HAO1 (0.43) HAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX KMT2A 3943/4885CA12 843/4885MIF 4767/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX KMT2A 3943/4885CA12 843/4885MIF 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.